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Abstract: Vascular endothelial growth factor (VEGF) is important for maintaining healthy
endothelium, which is crucial for vascular integrity. In this paper, we show that VEGF stimulates
the nuclear translocation of endothelial differentiation-related factor 1 (EDF1), a highly conserved
intracellular protein implicated in molecular events that are pivotal to endothelial function. In the
nucleus, EDF1 serves as a transcriptional coactivator of peroxisome proliferator-activated receptor
gamma (PPARγ), which has a protective role in the vasculature. Indeed, silencing EDF1 prevents
VEGF induction of PPARγ activity as detected by gene reporter assay. Accordingly, silencing EDF1
markedly inhibits the stimulatory effect of VEGF on the expression of FABP4, a PPARγ-inducible gene.
As nitric oxide is a marker of endothelial function, it is noteworthy that we report a link between
EDF1 silencing, decreased levels of FABP4, and nitric oxide production. We conclude that EDF1 is
required for VEGF-induced activation of the transcriptional activity of PPARγ.
Keywords: endothelial cells; vascular endothelial growth factor; Peroxisome proliferator-activated
receptor γ; Endothelial Differentiation-related factor 1
1. Introduction
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ubiquitous ligand-inducible
transcription factor belonging to the nuclear receptor superfamily [1]. PPARγ, which is highly
expressed in adipose tissue, is the master regulator of adipocyte differentiation and is fundamental for
mature adipocyte function [2–4]. PPARγ is also implicated in glucose homeostasis as it upregulates
genes involved in glucose uptake and controls the expression of adipokines, thereby having an
effect on insulin sensitivity [3,5,6]. It is now clear that PPARγ plays an important protective role
in the vasculature. Its activity has been proven both in smooth muscle cells, where it has a role in
the regulation of vascular tone [7], and in endothelial cells (EC), where it exerts anti-inflammatory
and antioxidant effects [8]. In endothelial-specific PPARγ−/− mice, loss of PPARγ contributes
to endothelial dysfunction associated with enhanced production of free radicals and exacerbated
inflammation [9]. Accordingly, human and animal studies indicate that thiazolidinediones (TZD),
which are largely utilized as antidiabetic drugs and PPARγ activators, attenuate vascular diseases
including atherosclerosis [10,11]. Post-translational modifications—including phosphorylation,
acetylation, and sumoylation—are important in carving PPARγ-driven gene expression [12]. Another
layer of control over PPARγ activity depends on its interactions with coactivators and corepressors [12],
which regulate transcriptional activity by reshaping chromatin structure via histone deacetylases
and histone acetyltransferases [13]. Indeed, upon activation by small natural lipophilic ligands or
synthetic agonists, the conformation of PPARγ changes—corepressors are released and coactivators
are recruited [3]—thus resulting in transcriptional activation.
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Endothelial differentiation-related factor 1 (EDF1), a highly conserved intracellular protein of
148 amino acids, has been identified as one of PPARγ’s coactivators [14,15]. Initially, the role of EDF1 as a
transcriptional coactivator was described in the silkworm Bombyx mori and in Drosophila melanogaster where
EDF1 stimulates the activity of the FTZ-F1 nuclear receptor [16]. At the time, EDF1 was demonstrated
to serve as a coactivator for several transcription factors [17,18]. This included some nuclear receptors
implicated in lipid metabolism, such as steroidogenic factor 1, liver receptor homologue 1, liver X receptor
α and, as mentioned above, PPARγ [14,15]. In particular, in 3T3-L1 preadipocytes, EDF1 is required for
PPARγ-mediated differentiation and gene expression programs [15]. In human macrovascular EC EDF1
was described as a factor implicated in differentiation and spatial organization [19]. In these cells EDF1
is localized mainly in the cytosol where it binds calmodulin [20] under basal conditions. In response to
various stimuli, it is translocated to the nucleus where it interacts with the TATA box-binding protein [20].
Apart from its pivotal role in vasculogenesis and angiogenesis, VEGF is essential for endothelial
polarity and survival, thus contributing to the integrity of mature vessels [21]. This issue is relevant since
ECs are key players in organogenesis as well as in promoting adult organ maintenance. To this purpose,
it is noteworthy that VEGF is a critical component of the cross-talk between organs and tissues and the
vessels [21].
For this study, we considered three known facts: (1) PPARγ ligands influence VEGF action [8];
(2) PPARγ contributes to maintain normal vascular function [7–11]; and (3) EDF1 modulates the activity
of PPARγ [14,15]. We used these factors to investigate whether EDF1 acts as a regulator of PPARγ
activity in human macrovascular EC under normal culture conditions and after treatment with VEGF.
2. Results
2.1. Translocation of EDF1 to the Nucleus in Response to VEGF
Initially, we evaluated whether VEGF modulates the total amounts of EDF1 and PPARγ in human
umbilical vein endothelial cells (HUVEC). Confluent cells were treated with VEGF (50 ng/mL) for
different times. We performed Real-Time PCR as well as western blot analysis and found no modulation
in the levels of EDF1 and PPARγ after 8, 12, and 24 h exposure to VEGF (Figure 1 and Supplementary
S1). Because EDF1 translocates to the nucleus when HUVEC are stimulated with the phorbol ester
12-O-Tetradecanoylphorbol-13-acetate (TPA) or with forskolin [20,22], we evaluated the subcellular
localization of EDF1 in cells treated with VEGF (50 ng/mL) for different times. By immunofluorescence,
EDF1 was detectable both in the cytosol and in the nucleus of unstimulated cells. After being treated
with VEGF, EDF1 accumulated in the nuclei after 1 h and remained nuclear-associated for the following
24 h (Figure 2a and Supplementary S2a). Western blot on nuclear and cytosolic fractions isolated after
1 h treatment with VEGF confirmed these results (Figure 2b and Supplementary S2b).Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  3 of 9 
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endothelial cells (HUVEC) were treated with 50 ng/mL of vascular endothelial growth factor (VEGF) for 
0, 8, 12, and 24 h. (a) Real-Time PCR was performed on RNA samples. Two different experiments in 
triplicate were performed; (b) cell lysates were analyzed by western blot using antibodies against EDF1, 
PPARγ, and actin. A representative blot is shown. 
 
Figure 2. Subcellular localization of EDF1 in cells treated with VEGF. (a) HUVEC were treated with 
VEGF (50 ng/mL) for 1, 8, 12, and 24 h. Immunofluorescence was performed using anti-EDF1 
immunopurified immunoglobulin G (IgGs) and rhodamine-conjugated anti-rabbit IgGs; (b) HUVEC 
were treated with VEGF (50 ng/mL) for 1 h. Western blot was performed on nuclear and cytosolic 
fractions using antibodies against EDF1. GAPDH and TBP were used as cytosolic and nuclear 
markers, respectively. A representative blot is shown. 
2.2. Interaction between EDF1 and PPARγ in HUVEC 
We evaluated the interaction between EDF1 and PPARγ in HUVEC treated with VEGF (50 
ng/mL) for various times. Cell lysates were immunoprecipitated with antibodies against PPARγ. 
Western blot was performed on the immunoprecipitates to detect EDF1. EDF1 and PPARγ interacted 
in nonstimulated cells and VEGF did not significantly modulate this interaction at the time points 
tested (Figure 3 and Supplementary S3). 
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Figure 2. Subcellular localization of EDF1 in cells treated with VEGF. (a) HUVEC were treated
with VEGF (50 ng/mL) for 1, 8, 12, and 24 h. Immunofluorescence was performed using anti-EDF1
immunopurified immunoglobulin G (IgGs) and rhodamine-conjugated anti-rabbit IgGs; (b) HUVEC
were treated with VEGF (50 ng/mL) for 1 h. Western blot was performed on nuclear and cytosolic
fractions using antibodies against EDF1. GAPDH and TBP were used as cytosolic and nuclear markers,
respectively. A representative blot is shown.
2.2. Interaction between EDF1 and PPARγ in HUVEC
We evaluated the interaction between EDF1 and PPARγ in HUVEC treated with VEGF (50 ng/mL)
for various times. Cell lysates were immunoprecipitated with antibodies against PPARγ. Western
blot was performed on the immunoprecipitates to detect EDF1. EDF1 and PPARγ interacted in
nonstimulated cells and VEGF did not significantly modulate this interaction at the time points tested
(Figure 3 and Supplementary S3).Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 9 
 
 
Figure 3. The interaction between EDF1 and PPARγ in HUVEC treated with VEGF. HUVEC were treated 
with VEGF (50 ng/mL) for different times. Cell lysates were immunoprecipitated with monoclonal 
antibodies against PPARγ and analyzed by western blot using rabbit antibodies against EDF1 (upper 
panel). The filter was then probed with rabbit anti-PPARγ antibodies to verify the equal amounts of 
immunoprecipitated proteins (lower panel). Densitometric analysis was performed using ImageJ 
software. EDF1/PPARγ ratio was calculated on three blots from separate experiments ± standard deviation. 
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Figure 3. The int r ction between EDF1 and PPARγ in HUVEC treated with VEGF. HUVEC
were treated with VEGF (50 ng/mL) for different times. Cell lysates were immunoprecipitated
with monoclonal antibodies against PPARγ and analyzed by western blot using rabbit antibodies
against EDF1 (upper panel). The filter was then probed with rabbit anti-PPARγ antibodies to
verify the equal amounts of immunoprecipitated proteins (lower panel). Densitometric analysis
was performed using ImageJ software. EDF1/PPARγ ratio was calculated on three blots from separate
experiments ± standard deviation.
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2.3. Effect of Silencing EDF1 in VEGF-Induced PPARγ Activity
To study if EDF1 contributes to PPARγ transcriptional activity in VEGF-treated HUVEC,
we utilized HUVEC with stably silenced EDF1, denominated αs1 cells [23]. We used HUVEC
transfected with a nonsilencing sequence [23] as the control (CTR). It is noteworthy that PPARγ
did not change in αs1 cells compared to their controls as demonstrated by western blot (Figure 4a and
Supplementary S4).
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transfected with a scrambled no silencing sequence (used as control) (CTR). Cell l sates were analyzed
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We then transfected subconfluent αs1 cells and the control cells with a vector expressing luciferase
under the control of a PPARγ responsive consensus (pDR1) [24]. After 4 h, the cells were treated with
VEGF (50 ng/mL) and luciferase activity was measured after 24 h. While VEGF stimulated PPARγ
transcriptional activation in control cells, this effect was prevented by silencing EDF1 (Figure 4b).
To reinforce this finding, we analyzed the expression of a PPARγ downstream target gene, i.e., fatty
acid-binding protein 4 (FABP4), which is known to be upregulated in HUVEC after 24 h exposure to
VEGF [25]. We cultured HUVEC in the presence of VEGF (50 ng/mL) for 24 h. Using Real-Time PCR,
we confirmed the overexpression of FABP4 RNA in control HUVEC treated with VEGF. In αs1 cells,
which downregulate EDF1, the induction was significantly reduced (Figure 4c).
Because HUVEC with silenced FABP4 produce lower amounts of nitric oxide (NO) than controls
and are insensitive to the stimulatory effect of VEGF [26], we measured the release of NO in αs1 cells
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and their controls that were treated or not with VEGF for 24 h. Figure 4d shows that while VEGF
induced NO secretion in control cells, it did not exert any significant effect in αs1 cells.
3. Discussion
ECs line the inner face of blood vessels and their integrity is fundamental for vascular homeostasis
and circulatory function [27]. Indeed, ECs are implicated in maintaining blood fluidity, governing
leukocyte trafficking and vascular tone, and in regulating immune response. Consequently, it is not
surprising that endothelial dysfunction, which is characterized by a pro-oxidant and pro-inflammatory
phenotype, orchestrates events leading to cardiovascular diseases. Moreover, healthy endothelial cells
are crucial for the maintenance of normal energy metabolism and, therefore, physiologic function of
all tissues [27]. There is now evidence that PPARγ is a key regulator of endothelial function [21,27]
and, accordingly, PPARγ activators inhibit the expression of proinflammatory molecules and the
synthesis of free radicals [27]. Many factors contribute to the integrity of the endothelium including
VEGF, which is critical for endothelial survival and barrier function in mature vessels [21]. On these
bases, we investigated whether VEGF activates PPARγ in HUVEC by recruiting the transcriptional
co-activator EDF1. We found that while VEGF does not change the total amounts of EDF1, it rapidly
induces EDF1 nuclear translocation, which is maintained for 24 h. These results are in accordance
with previous data showing EDF1 nuclear accumulation in HUVEC treated with the phorbol ester
12-O-Tetradecanoylphorbol-13-acetate (TPA) and the forskolin, which raise intracellular cAMP [20,23].
Interestingly, TPA, forskolin, and VEGF all induce the phosphorylation of EDF1 [20,22,23], and we
hypothesize that phosphorylation has a role in increasing the nuclear accumulation of EDF1. It should
be noted that EDF1 does not have a nuclear targeting sequence, and it is likely that a shuttle
protein drives EDF1 to the nucleus. If this is the case, we postulate that VEGF enhances this
shuttle mechanism. In the nucleus, VEGF stimulates the transcriptional activity of PPARγ in an
EDF1-dependent manner. Indeed, silencing EDF1 prevents VEGF-induced PPARγ activity. Since VEGF
increases the transcriptional activity of PPARγ in endothelial cells without altering its interaction with
EDF1, it is possible that VEGF induces a specific PPARγ ligand or inhibits a corepressor, thus altering
the balance between various transcriptional corepressors and coactivators. These results highlight an
important difference between adipocytes and endothelial cells. In 3T3-L1 preadipocytes, silencing
EDF1 decreases the total amounts of PPARγ and, in parallel, its transcriptional activity [15]. By contrast,
in HUVEC, silencing EDF1 affects only its transcriptional activity.
We also evaluated the expression of a PPARγ-responsive gene in HUVEC with silenced EDF1.
In particular, we focused on the modulation of FABP4, which encodes a cytoplasmic protein that has
a role in endothelial fatty acid metabolism and free radical production. It also impairs proliferation
and sprout elongation and impacts on nitric oxide synthesis [25,28]. Interestingly, pioglitazone—
an insulin-sensitizing thiazolidinedione and a PPARγ agonist—increases FABP4 levels. In this study,
we show that the activation of PPARγ by VEGF induces FABP4 expression through the involvement of
EDF1. Indeed, silencing EDF1 markedly inhibits the stimulatory effect of VEGF on FABP4 expression.
It is known that VEGF induces FABP4 through the Delta-like ligand (DLL) 4/NOTCH1 pathway [25].
Our results indicate that also PPARγ contributes to VEGF induction of FABP4 in HUVEC.
NO is a pivotal mediator of VEGF-induced responses and is essential for vascular function [29].
The regulation of NO production is very complex and it is noteworthy that both PPARγ and FABP4
are involved. Indeed, in endothelial cells, the activation of PPARγ increases NO release [30] while
the downregulation of FABP4 reduces it [28]. To this purpose, we show that αs1 cells do not respond
to VEGF by increasing NO release. We hypothesize that the downregulation of EDF1 impairs
VEGF-induced activation of PPARγ with consequent reduction of FABP4 and NO synthesis.
We conclude that VEGF induces EDF1 translocation to the nucleus where it acts as a transcriptional
coactivator of PPARγ. The transcriptional activation of PPARγ increases the expression of FABP4,
which is known to regulate NO production. Because NO is a marker of endothelial function, our results
substantiate that PPARγ activation has a role in maintaining the integrity of vessels and highlight
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EDF1 as a novel player in the complex regulation of PPARγ transcriptional activity in the endothelium.
On these bases, we propose that EDF1 makes an important contribution to maintain endothelial
integrity, and this may be crucial in the prevention of cardiovascular diseases.
4. Materials and Methods
4.1. Cell Culture
HUVEC—widely accepted as a model of macrovascular EC—were obtained from the American
Type Culture Collection (ATCC) and cultured in M199 containing 10% fetal bovine serum, 1 mM
glutamine, endothelial cell growth factor (150 µg/mL), 1 mM sodium pyruvate and heparin
(5 units/mL) on 2% gelatin-coated dishes [20]. In some experiments, we utilized HUVEC stably
transfected to silence EDF1 (αs1), while their controls (CTR) were transfected with a scrambled,
nonsilencing sequence as previously described [22].
4.2. Western Blot and Immunoprecipitation
Western blot was performed as described with antibodies against EDF1 (AVIVA Systems Biology
Corporation, San Diego, CA, USA), rabbit anti-PPARγ, and anti-actin (Sigma Aldrich, St. Louis, MO,
USA) [15]. Secondary antibodies were labeled with horseradish peroxidase (GE Healthcare, Milano,
Italy). The immunoreactive proteins were visualized with the SuperSignal chemiluminescence kit
(ThermoFisher Scientific, Waltham, MA, USA). To coimmunoprecipitate EDF1 and PPARγ, lysates were
immunoprecipitated using monoclonal antibodies against PPARγ. Nonimmune immunoglobulin G
(IgGs) were used as controls (Supplementary S3b). After binding to protein G-Sepharose, the samples
were processed for western blot with rabbit anti-EDF1 antibodies. Nuclear and cytosolic fractions
were obtained as described [20] and processed by western blot using antibodies against EDF1,
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and anti-TATA Binding Protein (TBP)
(Santa Cruz Biotechnology-Tebu Bio, Huissen, The Netherlands). All the experiments were repeated
at least three times. One representative blot is shown in the figures. Densitometry was performed
using ImageJ software (1.50i, National Institutes of Health, Bethesda, MD, USA) on three blots and
expressed using an arbitrary value scale. Results are shown as the mean ± standard deviation of three
separate experiments.
4.3. Immunofluorescence Staining
Subconfluent HUVEC on gelatin-coated coverslips were treated or not treated with
VEGF (50 ng/mL) (PeproTech, London, UK), fixed in phosphate-buffered saline containing
3% paraformaldehyde and 2% sucrose pH 7.6, permeabilized with HEPES-Triton 1%, incubated
with anti-EDF1 immunopurified IgGs, and stained with rhodamine-conjugated anti-rabbit IgGs [20].
Staining with rabbit nonimmune IgGs did not yield any significant signal.
4.4. Reporter Gene Assay
To study PPARγ activity, subconfluent HUVEC with silenced EDF1 and their controls were
transfected with plasmids pDR1-Luc (0.2 µg/cm2), using Arrest-in transfection reagent (Invitrogen)
as described [24]. Luciferase activity was measured after 24 h of treatment with VEGF (50 ng/mL)
using a luminometer. The transfection efficiency was normalized against a cotransfected reporter
plasmid phRL-TK encoding Renilla luciferase (5 ng/cm2), by dividing the firefly luciferase activity by
the Renilla luciferase activity according to the Dual-Luciferase Reporter Assay kit manual (Promega,
Madison, WI, USA). The experiments were performed in triplicate and the results are shown as the
mean ± standard deviation of three separate experiments.
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4.5. Real-Time-PCR
Total RNA was extracted using the PureLink RNA Mini kit (Ambion, Thermo Fisher Scientific,
Waltham, MA, USA). After quantification, equivalent amounts of total RNA were assayed by first
strand cDNA synthesis using SuperScript II RT (Invitrogen, Carlsbad, CA, USA). Real-time PCR
was performed at least two times in triplicate on the 7500 FAST Real-Time PCR System instrument
using TaqMan Gene Expression Assays (Life Technologies, Monza, Italy). We analyzed FABP4
(Hs01086177_m1), EDF1 (Hs00610152_m1), and PPARγ (Hs01115513_m1) while the housekeeping
gene GAPDH (Hs99999905_m1) was used as an internal reference gene. Relative changes in gene
expression were analyzed by the 2−∆∆Ct method.
4.6. NO Release
Griess assay was used to measure NO in cell culture media [23]. In particular, media were mixed
1:1 with fresh Griess solution and the absorbance was measured at 550 nm. The concentration of
nitrites in the media were determined using calibration curve generated using known concentration
of NaNO2 solutions. The experiment was performed in triplicate and the results are shown as the
mean ± standard deviation of three separate experiments.
4.7. Statistical Analysis
Statistical significance was determined using the Student’s t test and set at p values less than 0.05.
In the figures, * p < 0.05, ** p < 0.01, *** p < 0.001.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/7/
1830/s1.
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